Ecallantide

What it's for

Ecallantide is a recombinant peptide/protein therapeutic that inhibits plasma kallikrein. It treats acute attacks of hereditary angioedema (HAE (hereditary angioedema, dangerous swelling attacks)) in appropriate patients.

What it does for the body

It treats acute attacks of hereditary angioedema (HAE (hereditary angioedema, dangerous swelling attacks)) in appropriate patients. It is not a daily prophylactic for all HAE (hereditary angioedema, dangerous swelling attacks) types by itself (other agents fill that role). People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

Blocking plasma kallikrein reduces bradykinin generation. Excess bradykinin drives vascular permeability and swelling in HAE (hereditary angioedema, dangerous swelling attacks) attacks. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Ecallantide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Skin research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Ecallantide — FDA.gov search
• ClinicalTrials.gov search: Ecallantide — U.S. clinical trials registry
• Drugs@FDA search: Ecallantide — FDA drug database (if approved)
• PubMed search: Ecallantide — NCBI PubMed
• PubMed Central search: Ecallantide — NCBI PMC

Reference

No ref on file.